Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy

British Journal of Cancer(2021)10.1038/s41416-021-01400-2Source: DataRank Database

Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy is a research paper published in British Journal of Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 209 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access209 citations

Download PDF

Cite:

Linked data & code

geo dbgap doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 16.88)OA: greenTopics (45)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Chloe M. Fugle,Xiaofeng Wang ORCID,Chao Cheng ORCID,Evelien Schaafsma ORCID

Live enrichment

PubMed:33981015 PMC:PMC8329209 OpenAlex:https://openalex.org/W3160993535

U.S. Department of Health & Human Services | National Institutes of Health

Grant: T32 AI007363

U.S. Department of Health & Human Services | National Institutes of Health

Grant: 1R21CA227996

Cancer Prevention and Research Institute of Texas

Grant: RR180061

NCI NIH HHS

Grant: R21 CA227996

National Institutes of Health

Grant: 5T32AI007363-23

Immunobiology of Myeloid and Lymphoid Cells

National Institutes of Health

Grant: 5R21CA227996-02

Computational Identification of new candidate drugs for lung cancer treatment

U.S. Department of Health & Human Services | National Institutes of Health

FWCI

16.88

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: Springer TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8329209

publisherhttps://www.nature.com/articles/s41416-021-01400-2.pdf

publisherhttps://www.nature.com/articles/s41416-021-01400-2

journalhttps://doi.org/10.1038/s41416-021-01400-2

Fields of Study

Cancer Immunotherapy and Biomarkersvaccines and immunoinformatics approachesImmunotherapy and Immune Responses0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

FemaleHumansImmunotherapyMaleNeoplasmsPrognosisHistocompatibility Antigens Class ICD4-Positive T-LymphocytesUp-RegulationGene Expression Regulation, NeoplasticSurvival AnalysisTreatment OutcomeSequence Analysis, RNANeutrophil InfiltrationGene Expression Profiling

Keywords

CancerImmunotherapyMedicineHuman leukocyte antigenCancer immunotherapyOncologyImmunologyCancer researchInternal medicineAntigenCD4-Positive T-LymphocytesMaleSequence Analysis, RNAGene Expression ProfilingHistocompatibility Antigens Class IPrognosisSurvival AnalysisUp-RegulationGene Expression Regulation, NeoplasticTreatment OutcomeNeutrophil InfiltrationNeoplasmsHumansFemale

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Pervasiveness of HLA allele-specific expression loss across tumor types

10.6084/m9.figshare.22616998.v1figshare

Additional file 1 of Pervasiveness of HLA allele-specific expression loss across tumor types

10.6084/m9.figshare.22616998figshare

Additional file 6 of Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer

10.6084/m9.figshare.22619585.v1figshare

Additional file 6 of Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer

10.6084/m9.figshare.22619585figshare

Additional file 7 of Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer

10.6084/m9.figshare.22619588.v1figshare

Additional file 7 of Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer

10.6084/m9.figshare.22619588figshare

Additional file 1 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804855.v1figshare

Additional file 1 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804855figshare

Additional file 5 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804867.v1figshare

Additional file 5 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804867figshare

Additional file 6 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804870.v1figshare

Additional file 6 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804870figshare

Additional file 7 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804873.v1figshare

Additional file 7 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804873figshare

Additional file 8 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804876.v1figshare

Additional file 8 of Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

10.6084/m9.figshare.23804876figshare

Additional file 2 of Identification and validation of eight lysosomes-related genes signatures and correlation with immune cell infiltration in lung adenocarcinoma

10.6084/m9.figshare.24804814.v1figshare

Additional file 2 of Identification and validation of eight lysosomes-related genes signatures and correlation with immune cell infiltration in lung adenocarcinoma

10.6084/m9.figshare.24804814figshare

Additional file 1 of Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response

10.6084/m9.figshare.25097346.v1figshare

Additional file 1 of Integrative HLA typing of tumor and adjacent normal tissue can reveal insights into the tumor immune response

10.6084/m9.figshare.25097346figshare